FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma January 6, 2023January 20, 2023 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA grants Priority Review to Roche’s Lunsumio for…FDA approves Roche’s Lunsumio, a first-in-class…CHMP recommends EU conditional approval of Roche’s…European Commission approves Roche’s first-in-class…FDA accepts supplemental Biologics License…New pivotal data demonstrate clinical benefit of…
